Wellnex Life Limited (Wellnex, WNX or Company) (ASX: WNX), owner and developer of some of Australia's leading health brands, has recently published a key ASX announcement.
Wellnex Life Limited (ASX) ("Wellnex Life" or the "Company"), is pleased to provide an update on the proposed dual listing on the main market of the London Stock Exchange (LSE).
Announcement Highlights
- Wellnex Life, as announced on 23 April 2024, commenced the process of dual listing on the main market of the LSE after an extensive period of due diligence which included an institutional roadshow in the UK. Wellnex Life as part of the process, and as announced on 24 July 2024, completed a placement with UK-based high net worth and sophisticated investors at $1.40 per share.
- The strong support from UK-based investors validates the company’s decision to dual list on the LSE, which is home to the world’s largest consumer healthcare companies and with the Company expecting a significant percentage of its total revenue to come from the UK and Europe with the expansion of the Haleon arrangement and other initiatives.
Read the full Wellnex Life Company Update here.
To learn more about Wellnex Life and stay up to date with investor information, subscribe to the Company's Chairman’s List.
